SANDU PHARMACEUTICALS LTD
Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in

Dated:13.11.2021

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting with Scrip Code 524703.

A Meeting of the Board of Directors of the Company duly convened on Saturday, 13th November 2021 **at 05:00 p.m. and concluded at 08.00 p.m.** discussed the following business: -

1. Considered, Approved and took on record Unaudited Financial Results for the Quarter 30th September 2021.
2. Took Note of Resignation Letter submitted by Lalit R Gawde & Company,Internal Auditor of Mumbai w.e.f 15th November 2021
3. Took note of Statement of Utilizations and Deviations as per Regulation 32 of SEBI (LODR) Regulation 2015 for the Quarter ended 30th September 2021.

You are requested to kindly take the same on record.

Yours Faithfully,

For Sandu Pharmaceuticals Limited

SANDU PHARMACEUTICALS LIMITED GOA

Company Secretary

SANDU PHARMACEUTICALS LTD

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in, Web: www.sandu.in

Trusted in Ayurveda

Sandu Pharmaceuticals Ltd

STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 30/09/21

(Rs in Lakhs)

	Particulars	Quarter ended			Half Year ended		
		Quarter Ended 30-09- 2021	Corresponding Quarter Ending June 2021	Corresponding Quarter year ended 30-09-2020	Half Year ended 30-09-2021	Corresponding Half year ended 30-09-2020	Previous Year Ended 31 March 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From Operations	1,759.04	1,733.59	1,722.15	3,492.64	2,889.12	5,875.54
II	Other Income	2.78	2.34	6.69	5.12	9.07	19.34
III	Total Income (I+II)	**1,761.82**	**1,735.93**	**1,728.84**	**3,497.76**	**2,898.19**	**5,894.88**
IV	**EXPENSES**						-
							-
							-
	Cost of materials consumed	539.73	259.65	304.65	799.37	496.65	1,187.18
	Purchases of Stock-in-Trade	645.12	676.95	534.47	1,322.07	746.29	1,924.13
	Changes in inventories of finished goods,	-					
	Stock-in -Trade and work-in-progress	(184.22)	148.04	330.00	(36.18)	699.06	338.70
	Employee benefits expense	256.19	216.85	189.65	473.04	338.04	801.82
	Finance costs	4.80	3.83	(2.82)	8.63	4.33	11.49
	Depreciation and amortization expense	13.31	13.19	14.02	26.51	27.76	55.67
	Other expenses	421.84	358.97	304.28	780.81	525.49	1,407.80
							-
	Total expenses (IV)	**1,696.77**	**1,677.47**	**1,674.25**	**3,374.27**	**2,837.62**	**5,726.79**
							-
			-				-
V	Profit/(loss) before exceptional items and tax (I- IV)	**65.05**	**58.46**	**54.59**	**123.49**	**60.57**	**168.09**
VI	Exceptional Items	-					-
VII	Profit/(loss) before tax (V-VI)	65.05	58.46	54.59	123.49	60.57	168.09
	Tax expense:						-
VIII	(1) Current tax	20.03	16.27	14.65	36.30	16.65	55.71
	(2) Deferred tax	(0.28)	0.37	0.29	0.09	0.45	2.95
	(3) Short /Excess Proviison						0.18
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	**45.30**	**41.82**	**39.65**	**87.10**	**43.47**	**109.25**
							-
X	Profit/(loss) for the period (IX+XII)	**45.30**	**41.82**	**39.65**	**87.10**	**43.47**	**109.25**
XI	**Other Comprehensive Income**						-
	Items that will not be reclassified to Profit & Loss	-					
	Remeasurement gains/(losses) on post employment defined benefit plans		-				1.90
	Fair value changes of investments	13.74	5.98	7.87	19.72	22.55	58.30
					-		-
	Income tax relating to items that will not be reclassified to Profit & Loss account.	(1.53)	(0.66)	(0.82)	(2.19)	(2.34)	(7.79)
							-
XII	**Total other Comprehensive Income for the Period**	12.21	5.32	7.05	17.53	20.21	52.41
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	57.51	47.14	46.70	104.63	63.68	161.66
							-
							-
							-
	Paid Up Equity Capital						-
XIII	(Face Value of Rs 10/- Per share)	792.09	792.09	708.10	792.09	708.10	792.09
XIV	Earnings per equity share						
	(1) Basic	0.57	0.53	0.56	1.10	0.61	1.54
	(2) Diluted	0.49	0.48	0.56	0.99	0.61	1.54

For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141

Mumbai
Date :-13.11.2021

Regd. & Factory Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in
CIN:L24233GA1985PLC001587

ISO 9001:2015 CERTIFIED ORGANISATION

SANDU PHARMACEUTICALS LTD

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in, Web: www.sandu.in

SANDU Trusted in Ayurveda

Sandu Pharmaceuticals Ltd

STATEMENT OF ASSETS & LIABILITES FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2021

Sr no	Particulars	As at 30 th September 2021	As at 30 th March 2021
I	**ASSETS**		
	Non Current Assets		
	Property , plant & Equipment	632.68	646.57
	Right of use assets	956.66	963.98
	Other Intangible Assets	5.12	6.8
	Financial Assets		
	Investments	1,093.85	24.17
	Loan Receivable	-	
	Other Financial Asset	0.68	0.43
	Other current assets	-	
	Current Assets	**2,688.99**	**1641.95**
	Inventories	1,169.84	1113.79
	Financial Asset		
	Investments	-	-
	Trade Receivables	628.42	534.77
	Cash & Cash Equivalents	161.15	452.75
	Bank & other Cash Equivalents	213.29	712.83
	c) Other Current Assets	391.35	240.18
	Total of Curent Assets	**2,564.05**	**3054.32**
	TOTAL ASSETS	**5,253.07**	**4696.27**
	EQUITY & LIABILITIES		
	a) Equity Share Capital	792.09	792.09
	b)Other Equity	2,626.24	2557.02
	Total Equity	**3,418.33**	**3349.11**
II	**LIABILITIES**		
	Non -Current Liabilities		
	a)Financial liabilities		
	i) Borrowings	-	
	ii)Other Financial Liabilties		
	b) Deferred Tax	97.55	95.26
	Total Non current Liabilities	**97.55**	**95.26**
	Current Liability		
	a)Financial liabilities		
	Borrowings	-	1.92
	Trade Payables		
	Dues to Micro & Small Enterprises	3.74	2.34
	Other than Micro & Small Enterprises	1,072.56	664.69
	iii)other financial Liabilities		
	b) Other Current Liabilities	129.75	109.75
	c) Provisions	531.11	473.20
	Total current Liabilities	**1,737.16**	**1251.90**
	Total Liabilites	**5,253.07**	**4696.27**

For Sandu Pharmaceuticals Ltd

SANDU PHARMACEUTICALS LIMITED

Place :- Mumbai
Date :- 13 th November , 2021

Umesh Sandu
Managing Director
DIN :- 01132141

SANDU PHARMACEUTICALS LTD

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in, Web: www.sandu.in

SANDU PHARAMACEUTICALS LIMITED

Statement of Cash Flow for the Half year ended 30th Sept , 2021

Particulars	Year to date ended 30th Sept ,2021		Year to date ended 30st Sept , 2020	
	Amount (`)	Amount (`)	Amount (`)	Amount (`)
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		1,23,49,114		60,56,676
Adjustments for:				
Depreciation and amortisation expenses	26,51,174		27,75,703	
Finance costs	8,63,861		4,32,702	
Interest income	(5,03,244)		2,99,124	
Dividend income from equity instruments designated at FVTOCI	(9,551)		(13,209)	
Profit on sale of Property, Plant and Equipment				
		30,02,241		34,94,321
Operating profit / (loss) before changes in operating assets & liabilities		**1,53,51,355**		**95,50,997**
Changes in operating assets				
(increase) / decrease in inventories	(56,05,277)		6,58,86,991	
(increase) / decrease in Trade receivables	(93,64,926)		(3,11,05,240)	
(increase) / decrease in other operating assets	(1,03,12,594)		1,42,86,250	
Changes in operating liabilities				
(increase) / decrease in trade payables	4,09,27,127		(2,36,28,509)	
(increase) / decrease in other operating liabilities	41,60,917	1,98,05,247	57,07,572	3,11,47,064
Cash Generated from operation		**3,51,56,603**		**4,06,98,061**
Income Tax Paid		(48,05,027)		(8,86,294)
Net Cash flow from Operating activites		**3,03,51,575**		**3,98,11,767**
B. Cash flow from investing activities				
Purchases of Property, Plant and Equipment	(3,62,616)		(6,60,431)	
Fixed deposits placed with banks	4,99,29,502		(2,97,24,475)	
Interest received	5,03,244		(2,99,124)	
Dividend income from equity instruments designated at FVTOCI	9,551		13,209	
Purchase of Mutual fund designated at FVTOCI	(10,49,94,750)			
	-		-	
Net cash flow from / (used in) investing activities (B)		**(5,49,15,069)**		**(3,06,70,822)**
C. Cash flow from financing activities				
Repayment of Short-term borrowings	(1,92,679)		2,24,71,215	
Finance cost	(8,63,861)		(4,32,702)	
Dividend Paid	(35,40,500)			
Net cash flow from / (used in) financing activities (C)		**(45,97,040)**		**2,20,38,513**
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		**(2,91,60,534)**		**3,11,79,458**
Cash and cash equivalents at the beginning of the year		4,52,75,716		1,54,16,124
Cash and cash equivalents at the end of the year		**1,61,15,181**		**4,65,95,577**

For Sandu Pharmaceutcials Ltd

Dated : 13/11/2021
Place:Mumbai

Umesh Sandu
Managing Director
DIN :- 01132141

SANDU PHARMACEUTICALS LIMITED

SANDU PHARMACEUTICALS LTD

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in, Web: www.sandu.in

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 13th November, 2021. The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The Company has considered the possible impact of COVID-19 pandemic on its operations, liquidity position and recoverability of its asset balances at 30th September,2021 based on the internal and external information up to the date of approval of these financial results. The impact of COVID-19 may be different from that estimated as at the date of approval of these financial results and management will continue to monitor any material changes arising due to the impact of this pandemic on financial and operational performance of the Company and take necessary measures to address the situation.
4. The Figures for the quarter ended 31 st March, 2021 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.
6. The Above results are reviewed and recommended by the audit committee and approved by Board of Directors at the meeting held on 13th November ,2021 and there are no qualification in the audit report for the quarter ended , 30th September , 2021.

Date: - 13/11/2021

For Sandu Pharmaceuticals Ltd

SANDU PHARMACEUTICALS LIMITED

Umesh Sandu
Managing Director
DIN :- 01132141

Dileep & Prithvi
CHARTERED ACCOUNTANTS

"LIMITED REVIEW" REPORT ON THE UNAUDITED FINAICIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPEMBER, 2021

To,

The Board of Directors,
Sandu Pharmaceuticals Limited,
Plot No. 25, 26, 29 & 30,
Pilerne Industrial Estate, Marra,
Bardez, Goa-403511.

Dear Sirs,

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sandu Pharmaceuticals Limited** ("the Company") for the quarter and half year ended on 30th Sep, 2021, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind As 34), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.

3. We conducted our review in accordance with the Standard on Review Engagement *(SRE) 2410,* "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Dileep & Prithvi
Chartered Accountants
Firm Registration Number: 122290W

DILEEP & PRITHVI MUMBAI Regn. No.:- 122290W CHARTERED ACCOUNTANTS

Himmat Mali
(Partner)
Membership Number: 183378
UDIN- 21183378AAAACR1056

Place: Mumbai
Date: 13th November, 2021

4-A, 3rd Floor, Dahanukar Bldg., 480, Kalbadevi Road, Mumbai - 400 002. • Tel.: +91-22-22071185 / 40031184 • E-mail : contact@dileepprithvi.com
Web.: www.dileepprithvi.com